Scholarlink

Purpose <p>The aim of our study was to assess the mid-term efficacy and safety of the FRED&#xa0;X flow diverting stent (FDS) in the treatment of intracranial aneurysms. The FRED&#xa0;X FDS is relatively new with limited data on its longer-term effectiveness and safety profile.</p> Methods <p>Patients with intracranial aneurysms treated with the FRED&#xa0;X FDS at two UK centres, between March 2021 and July 2022 with at least 18&#xa0;months follow-up, were retrospectively reviewed. Clinical, procedural and imaging data was analyzed.</p> Results <p>Twenty-two patients with 24&#xa0;aneurysms treated with the FRED&#xa0;X device, and had completed at least 18&#xa0;months of follow-up, were included in this study. The rate of complete aneurysm occlusion (Raymond-Roy Class&#xa0;I) was 83.3% at a&#xa0;mean follow-up duration of 21.5 months. One case of major adverse event (4.3%) related to a&#xa0;post-procedural stroke which is also the only case of permanent neurological deficit (4.3%) in our cohort. Three cases of minor adverse events (13.0%) and 2&#xa0;cases of asymptomatic adverse events (8.7%) were also recorded.</p> Conclusion <p>Use of the FRED&#xa0;X FDS to treat intracranial aneurysms has acceptable safety profile and efficacy in the mid-term.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment of Intracranial Aneurysms with the FRED X Flow Diverter Stent: Mid-term Angiographic and Safety Results

  • 期刊论文

  • 发表日期：

    2025年1月23日

查看全文
  • David W. Wen,
  • James Ayre,
  • Mani Puthuran,
  • Paul Maliakal,
  • Souhyb Masri,
  • Richard Pullicino,
  • Aubrey Smith,
  • Feyi Babatola,
  • Gilbert Gravino,
  • Nasr Abdelsalam,
  • Hamed Nejadhamzeeigilani,
  • Arun Chandran

摘要

Purpose

The aim of our study was to assess the mid-term efficacy and safety of the FRED X flow diverting stent (FDS) in the treatment of intracranial aneurysms. The FRED X FDS is relatively new with limited data on its longer-term effectiveness and safety profile.

Methods

Patients with intracranial aneurysms treated with the FRED X FDS at two UK centres, between March 2021 and July 2022 with at least 18 months follow-up, were retrospectively reviewed. Clinical, procedural and imaging data was analyzed.

Results

Twenty-two patients with 24 aneurysms treated with the FRED X device, and had completed at least 18 months of follow-up, were included in this study. The rate of complete aneurysm occlusion (Raymond-Roy Class I) was 83.3% at a mean follow-up duration of 21.5 months. One case of major adverse event (4.3%) related to a post-procedural stroke which is also the only case of permanent neurological deficit (4.3%) in our cohort. Three cases of minor adverse events (13.0%) and 2 cases of asymptomatic adverse events (8.7%) were also recorded.

Conclusion

Use of the FRED X FDS to treat intracranial aneurysms has acceptable safety profile and efficacy in the mid-term.